iXCells Biotechnologies USA Inc., a provider of human cell-based solutions and custom iPSC services, has delivered over 500 characterized induced pluripotent stem cell (iPSC) lines as part of a multi-year collaboration with a global biotechnology company. The collaboration leverages iXCells’ iPSCore platform, which enables the large-scale generation of well-characterized patient-derived iPSC lines, to support the discovery and development of novel therapeutics. To date, iXCells has deliver...